Veru(US:VERU)2026-02-26 21:22Summary of Veru's Presentation at Oppenheimer's 36th Annual Healthcare Life Sciences Conference Company Overview - Company: Veru Inc. - Ticker: V - Focus: Development of enobosarm, a selective androgen receptor modulator, in combination with GLP-1 for obesity treatment Key Points and Arguments Drug Development and Clinical Trials - Veru has pivoted to combine enobosarm with GLP-1, aiming to address muscle loss associated with GLP-1 treatments [2][3] - The Phase 2b QUALITY study showed positive results, and a new Phase 2b PLATEAU study is set to start this quarter [2][6] - Enobosarm has undergone 27 clinical trials, with 6 focusing on muscle endpoints, demonstrating its potential to improve muscle mass and physical function [3][4] Addressing Muscle Loss in Older Patients - GLP-1 treatments can lead to a 40%-50% loss of lean mass, which is particularly detrimental for patients over 60 [3] - Enobosarm is designed to preserve muscle while promoting fat loss, which is crucial for older patients to avoid functional limitations and increased mortality [3][4][9] - The combination of enobosarm and GLP-1 aims to mitigate the adverse effects of GLP-1 on muscle mass while enhancing cardiovascular benefits [4][10] Study Design and Expected Outcomes - The PLATEAU study will focus on patients with a BMI greater than 35, aged over 65, and will last for 68 weeks [16][17] - Primary endpoint: total body weight; secondary endpoints include physical function, mobility, and bone mineral density (BMD) [18][24] - An interim analysis will occur at 34 weeks, assessing lean body mass and fat mass [17] Regulatory Considerations - The FDA has indicated that incremental weight loss of at least 5% could serve as a primary endpoint for approval [10] - If weight loss is less than 5%, preservation of physical function could be a clinically significant endpoint for approval [25] - The FDA now considers total hip BMD as a surrogate endpoint for osteoporosis drug development, which could benefit enobosarm's approval pathway [11][26] Market Potential - Approximately 44 million Americans over 65 are on Medicare Part D, with half potentially benefiting from weight loss drugs [17] - The combination of enobosarm with GLP-1 could address unmet needs in the obesity treatment market, particularly for older patients [15] Competitive Landscape - Enobosarm is positioned as a unique agent that not only aids in weight loss but also preserves muscle and improves bone health, distinguishing it from other GLP-1 treatments [42][44] - Competitors like Scholar Rock, Regeneron, and Lilly have presented data on myostatin inhibitors, but enobosarm's oral formulation may offer advantages [21][22] Financial and Development Timeline - Veru reported $33 million in cash as of December 31, 2025, and is on track for the PLATEAU study to start in Q1 2026 [26][27] - Enrollment is expected to be completed by Q3 2026, with top-line data anticipated in Q4 2027 [27][51] Additional Important Information - Enobosarm is protected as a new chemical entity, with multiple layers of patent protection extending to 2046 [49][50] - The focus on muscle preservation and functional improvement in older patients is critical for addressing the safety issues associated with current obesity treatments [46][48] This summary encapsulates the key points from Veru's presentation, highlighting the company's strategic focus on addressing muscle loss in older patients through innovative drug development and regulatory strategies.